Heart attack is known medically as myocardial infarction (MI). It is an ischemic (lack of blood flow) event leading to destruction of cardiac tissue. It is most commonly caused by coronary artery disease which is very common in the United States, being a leading cause of morbidity and mortality.
Cardiac Conditions and OC Regenerative Medicine
Contractile function of the heart is impaired by impaired or destroyed myocytes in the setting of cardiac ischemia. Cell therapy offers a potential for the myocyte destruction seen with cardiac ischemia. Data supporting the use of stem cells to regenerate damaged myocardium is accumulating. The safety of adult mesenchymal stem cells to treat cardiac disease has been demonstrated in clinical trials. Most of these studies have shown positive clinical results. Deployment methods and harvesting location have varied in these studies so it is unclear which source of mesenchymal cells is optimal for cardiac regeneration but adipose derived cells appear to be highly effective in this area.
Congestive heart failure (CHF) is a common cause of hospitalizations. It also can be lethal, contributing to over 50,000 deaths annually. CHF typically results from ischemic disease but is also associated with cardiomyopathy. Cardiomyopathy (deterioration in heart muscles) may be caused by infection and other causes. Cardiomyopathy causes diminishes the hearts ability to pump blood. Stem cells offer a potential new avenue for treating CHF and cardiomyopathy.
The effect of SVF (rich in mesenchymal stem cells and growth factors) on damaged myocardium is being studied at OC Regenerative Medicine. The anti-inflammatory and regenerative properties of adult stem cells to mitigate cardiac ischemia is being researched around the world. Our protocol involves intravenous deployment. It is done at our outpatient facility using local anesthetic. The entire cellular surgical procedure takes approximately 3 hours.